TY - T1的结核分枝杆菌< em > < / em >borderline rpoB mutations: emerging from the unknown JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00783-2021 VL - 58 IS - 3 SP - 2100783 AU - Van Deun, Armand AU - Decroo, Tom AU - Aung, Kya Jai Maug AU - Hossain, Mohamed Anwar AU - Gumusboga, Mourad AU - De Rijk, Willem Bram AU - Tahseen, Sabira AU - de Jong, Bouke Catherine AU - Rigouts, Leen Y1 - 2021/09/01 UR - //www.qdcxjkg.com/content/58/3/2100783.abstract N2 - Rifampicin drives the efficacy of the current first-line treatment regimen for tuberculosis (TB) [1]. Mutations in the rpoB gene cause rifampicin resistance (RR) of varying levels. Common mutations typically confer high-level, “high-confidence” resistance, providing a selective advantage to Mycobacterium tuberculosis during treatment at low fitness cost [2]. Growth-based phenotypic drug-susceptibility testing (pDST) is very reliable for high-confidence mutations. Mutations conferring low-level resistance at high fitness cost are easily lost during primary culture or will cause phenotypically false-susceptible results if not given enough time for growth, especially with the widely used automated MGIT 960 DST [3]. Due to disagreement on their significance, such rpoB mutations were called “disputed”.Despite their name, borderline rpoB mutations are correlated with unfavourable outcomes when rifampicin-throughout treatment is used. They may become the drivers of rifampicin-resistant tuberculosis. Second-line treatment is recommended. https://bit.ly/3nbkZjtWe thank the clinic and laboratory staff of Damien Foundation Bangladesh as well as the staff of the Mycobacteriology laboratory of the Institute of Tropical Medicine in Antwerp. ER -